TY - JOUR
T1 - Formulation and evaluation of irbesartan nanosuspension for dissolution enhancement
AU - Khushboo, Mistry
AU - Naik, Kavya
AU - Vasanthi,
AU - Menezes, Alicia
AU - Naha, Anup
AU - Koteshwara, K. B.
AU - Girish Pai, K.
PY - 2017/9/1
Y1 - 2017/9/1
N2 - Irbesartan, an angiotensin receptor blocker, a BCS class II drug is effective in lowering blood pressure but is having low aqueous solubility and low bioavailability. Hence, the present study was aimed to prepare and evaluate nanosuspension of Irbesartan for enhancement of dissolution. Preformulation studies like, DSC, FTIR was performed to evaluate the drug excipient compatibility. A full factorial method was utilized to study the effect of various factors such as surfactant concentration, sonication amplitude and sonication time on Irbesartan nanosuspension in two levels using Design Expert 10 software. In vitro drug release of optimized and pure drug was performed in pH 1.2 and pH 6.8 buffers. FT-IR and DSC studies showed no interaction between the drug and the excipients. Optimized nanosuspension showed particle size (149.639 nm), PDI (0.195) and zeta potential (-5.639). The nanoparticle formulation showed a prolonged improved drug release for 24 hours in phosphate buffer pH 6.8 (89.09%) as compared to pure drug dispersion (67.69%)
AB - Irbesartan, an angiotensin receptor blocker, a BCS class II drug is effective in lowering blood pressure but is having low aqueous solubility and low bioavailability. Hence, the present study was aimed to prepare and evaluate nanosuspension of Irbesartan for enhancement of dissolution. Preformulation studies like, DSC, FTIR was performed to evaluate the drug excipient compatibility. A full factorial method was utilized to study the effect of various factors such as surfactant concentration, sonication amplitude and sonication time on Irbesartan nanosuspension in two levels using Design Expert 10 software. In vitro drug release of optimized and pure drug was performed in pH 1.2 and pH 6.8 buffers. FT-IR and DSC studies showed no interaction between the drug and the excipients. Optimized nanosuspension showed particle size (149.639 nm), PDI (0.195) and zeta potential (-5.639). The nanoparticle formulation showed a prolonged improved drug release for 24 hours in phosphate buffer pH 6.8 (89.09%) as compared to pure drug dispersion (67.69%)
UR - http://www.scopus.com/inward/record.url?scp=85040769711&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85040769711&partnerID=8YFLogxK
U2 - 10.5958/0974-360X.2017.00540.6
DO - 10.5958/0974-360X.2017.00540.6
M3 - Article
AN - SCOPUS:85040769711
SN - 0974-3618
VL - 10
SP - 3043
EP - 3048
JO - Research Journal of Pharmacy and Technology
JF - Research Journal of Pharmacy and Technology
IS - 9
ER -